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Objectives/Hypothesis: Indication for postoperative radiotherapy in patients with locally circumscribed tumors (pT1–
pT2) and a single ipsilateral lymph node metastasis (pN1) is debatable. The aim of this study was to evaluate the oncological
long-term outcome of patients with pT1-pT2 pN1 squamous cell carcinoma (SCC) of the oral cavity, the oropharynx, and the
hypopharynx without extracapsular spread (ECS) after a margin-negative surgical resection, who either received or did not
receive postoperative (chemo)radiotherapy.
Study Design: Retrospective case series.
Methods: The oncological outcome of patients with pT1-pT2 pN1 SCC without ECS was evaluated retrospectively. All
patients underwent primary tumor resection that included transoral laser microsurgery and neck dissection at an academic
tertiary referral center.
Results: Of 65 identified patients treated between 1986 and 2015 (18 oral cavity, 30 oropharynx, 17 hypopharynx),
21 (32%) received postoperative radiotherapy, and 44 (68%) were treated by surgery alone. The group of patients receiving
postoperative treatment showed a significantly superior 5-year disease-specific (94.4% vs. 73.2%, P = .029) and recurrence-
free survival (85.2% vs. 43.2%, P = .002), as well as a higher local control rate (90.2% vs. 64.9%, P = .042). The overall survival
was 71.4% vs. 62.6% (P = .53). The mean follow-up was 80.7 months.
Conclusions: Patients with locally circumscribed carcinomas and a single ipsilateral ECS-negative lymph node metastasis
seem to benefit from postoperative radiotherapy.
Key Words: Postoperative radiotherapy, head and neck cancer, early tumor, single lymph node metastasis, multimodal
treatment concept.
Level of Evidence: 4
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INTRODUCTION
Minimally invasive transoral laser microsurgery
(TLM) is an effective therapeutic option for locally cir-
cumscribed squamous cell carcinoma (SCC) of the oral cav-
ity, the oropharynx, and the hypopharynx, and is often
completed with a selective neck dissection (ND).1–3 Postop-
erative (chemo)radiotherapy (PORT) is well established in
cases of advanced neck disease and/or adverse features like
extracapsular tumor spread (ECS) as well as positive surgi-
cal margins.4–7 Nevertheless, it is debatable for patients
with locally circumscribed primaries (pT1–pT2) with a sin-
gle ipsilateral lymph nodemetastasis (pN1) and without the
previouslymentioned adverse features.6,8 One reason is that
no results of prospective randomized trials addressing this
topic are available. Only a few retrospective studies9–14 pro-
vide data upon which therapeutic recommendations and
rational clinical decisionmaking can be based.
The aim of the study was to provide a detailed presen-
tation of long-term oncological results of this rare patient
group that either received or did not receive PORT.
MATERIALS AND METHODS
Patients and Therapy
A retrospective analysis was conducted of patients with
pT1–pT2 pN1 M0 categorized SCC of the oral cavity (OSCC), oro-
pharynx (OPSCC), and hypopharynx (HPSCC) without ECS, who
received primary surgical treatment at an academic tertiary refer-
ral center. Time span of inclusion was between August 1986 and
October 2015, with subsequent systematic follow-up. Cases were
identified, and data were obtained from the hospital’s cancer data-
base and original medical records. This study was approved by
the institutional review board (Ethics Committee of the University
Medical Center Göttingen) according to the national regulation.
Cases with non-SCC, previous or simultaneous secondary
malignancies, simultaneous distant metastases, primaries
treated primarily in another hospital, and/or those treated by
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conventional surgery, flap reconstruction, primary (chemo-)radio-
therapy, and with palliative intent were excluded. Of the
remaining 807 patients who received primary CO2 TLM for pT1–
pT4a oral, oropharyngeal, or hypopharyngeal carcinomas,
430 (53.3%) were diagnosed with pT1–pT2 tumors. Among these,
76 (17.7%) revealed a single ipsilateral lymph node metastasis
after histopathological assessment. From this group, 11 cases
with ECS were excluded. Finally, 65 patients met the inclusion
criteria. Data of some patients were partially evaluated in previ-
ous studies.1,2,9,15 Laryngeal SCC were excluded, because only
four patients met the inclusion criteria.
Staging and Surgical Treatment
Preoperative staging to evaluate tumor burden and to
detect regional and distant metastasis or synchronous primary
tumors was performed as described previously.2 Diagnosis was
confirmed by histopathological assessment. Disease was staged
in accordance with the seventh edition of classification of the
Union for International Cancer Control16 and the American Joint
Committee on Cancer.17
Details on surgical technique were described previously by
Steiner et al.18–20 In all cases, negative-margin resection status
(R0) was ensured by histopathological assessment.
Treatment of the Neck
Neck dissections were described based on the standardized
terminology.21,22 Indications for a selective ND comprised a carci-
noma’s infiltration depth of ≥3 mm and/or suspicious lymph
nodes detected in the course of preoperative diagnostic assess-
ment. In general, a bilateral ND was performed in cases of a mid-
line localization of the local primary and/or clinically suspicious
lymph nodes bilaterally.
Histological Assessment
For patients with OPSCC, especially in the early years,
molecular diagnostics of human papillomavirus (HPV) status or
p16 expression was not performed routinely. Thus, if sufficient
TABLE I.
Patient and Disease Characteristics and Follow-up Data Stratified by Treatment Group.
Characteristic PORT, n = 21 No PORT, n = 44 P Value* Total, N = 65
All patients, no. (%) 21 (32.3%) 44 (67.7%) 65 (100%)
Year of initial diagnosis
1986–2000 14 (66.7%) 32 (72.7%) .615 46 (70.8%)
2001–2015 7 (33.3%) 12 (27.3%) 19 (29.2%)
Gender
Male 17 (81.0%) 36 (81.8%) .933 53 (81.5%)
Female 4 (19.0%) 8 (18.2%) 12 (18.5%)
Age, yr, mean  SD 57.7  7.5 55.9  8.1 56.5  7.9
Median (minimum–maximum) 59.1 (42.8–68.3) 55.3 (39.0–77.3) 57.0 (39.0–77.3)
<57 8 (38.1%) 25 (56.8%) .158 33 (50.8%)
>57 13 (61.9%) 19 (43.2%) 32 (49.2%)
Main localizations
OSCC 4 (19.0%) 14 (31.8%) .069 18 (27.7%)
OPSCC 14 (66.7%) 16 (36.4%) 30 (46.2%)
p16 positive 3 (21.4%) 6 (37.5%) .569 9 (30.0%)
p16 negative 2 (14.3%) 2 (12.5%) 4 (13.3%)
p16 undetermined 9 (64.3%) 8 (50.0%) 17 (56.7%)
HPSCC 3 (14.3%) 14 (31.8%) 17 (26.2%)
T categorization
pT1 8 (38.1%) 20 (45.5%) .575 28 (43.1%)
pT2 13 (61.9%) 24 (54.5%) 37 (56.9%)
Histopathologic differentiation
High 1 (4.8%) 0 (0.0%) .285 1 (1.5%)
Moderate 14 (66.7%) 34 (77.3%) 48 (73.8%)
Poor 6 (28.6%) 10 (22.7%) 16 (24.6%)
Tumor size within the lymph node, n = 44
Micrometastasis 1 (7.7%) 9 (29.0%) .123 10 (22.7%)
Macrometastasis 12 (92.3%) 22 (71.0%) 34 (77.3%)
Follow-up, mo
Mean  SD 93.4  48.5 74.6  51.2 80.7  50.7
Median (minimum–maximum) 88.3 (10.3–208.5) 64.4 (12.5–190.7) 75.7 (10.3–208.5)
*Pearson χ2 test.
HPSCC = hypopharyngeal squamous cell carcinoma; OPSCC = oropharyngeal squamous cell carcinoma; OSCC = oral squamous cell carcinoma;
PORT = postoperative (chemo)radiotherapy; SD = standard deviation.
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formalin-fixed paraffin embedded tissue was still available,
immunohistochemistry was performed to examine p16 expres-
sion to at least consider this surrogate marker for oncogenic
HPV infection.23,24 Therefore, the visualization system EnVision
FLEX+, Mouse, High pH (Link) (Dako, Agilent Technologies,
Santa Clara, CA; reference number K8002) combined with mono-
clonal p16 antibodies (Santa Cruz Biotechnology, Dallas, TX;
Cat# sc-56330, RRID: AB_785018) (1:50; pH 9) were applied.
Only OPSCCs that exhibited strong (≥75%) nuclear and cytoplas-
mic staining were classified p16 positive.23,24
Postoperative Therapy
Due to the retrospective design of this study and the long
inclusion period, the reason for application and nonapplication of
PORT in the individual case could not be identified. Moreover,
from 1986 to 2015, standardization of recommendations for
PORT were just evolving. In general, treatment decisions were
influenced by tumor- and patient-associated factors, such as by
the primary carcinoma’s extent, its histologically proven infiltra-
tion depth, histopathological grade, main localization, and more-
over the patient’s individual risk factors and the patient’s
individual decision following informed consent.
Radiotherapy was applied as described previously.25 From
August 1986 until December 1993 (11 patients), the schedule of
radiotherapy comprised two daily fractions separated by 6-hour
intervals. Over 6 weeks as a split-course regimen, maximum
fractions of 2.1 Gy (1.25 MV 60Co) were applied, with a total
radiation dose of 56 and 70 Gy to the neck bilaterally and pri-
mary tumor, respectively. From January 1994 to December 2004
(seven patients), normofractionated radiotherapy (2 Gy/d, five
times per week) was delivered by the application of parallel,
opposed lateral portals matched to a single anterior portal
encompassing the primary tumor and associated nodal drainage
sites up to a maximum dose of 50 Gy. One anterior portal was
used to cover the lower neck and supraclavicular node with
applying a dosage of 50 Gy at a 3 cm depth. Finally, the three-
dimensional (3D) conformal external beam radiotherapy tech-
nique was used for the boost to achieve a total dose of 60 Gy.
Since January 2005 (three patients), normofractionated (2 Gy/d,
five times per week), 3D conformal external beam radiotherapy
was administered from the beginning of radiotherapy. In the first
phase, a dose of 50 Gy was administered to the primary tumor,
the involved lymph node, and to the potential drainage sites on
both sides of the neck, including the supraclavicular region,
followed by a boost of up to 64 Gy covering the primary tumor
and involved lymph node. For the effect of radiosensitization pro-
vided by additional platinum-based chemotherapy, this concomi-
tant treatment was administered as described previously.25
Follow-up
Postoperatively, all patients were examined according to a
previously described follow-up regime.2 After five years without
recurrence, a patient was considered as cured. However, for
58.8% of all patients (n = 38), follow-up examinations continued
after 5 years.
Statistics
Descriptive analysis of observed values or quantities was
denoted by the respective mean value and corresponding stan-
dard deviation, median and/or absolute, and relative frequencies.
Pearson χ2 test was used to analyze frequency distributions.
Applying the Kaplan-Meier method,26 overall survival (OS),
disease-specific survival (DSS), recurrence-free survival (RFS),
and the local control rate (LCR) were calculated starting from
the date of primary surgery.
Regarding OS, death for any reason was considered as an
event, and patients alive at the last follow-up were censored.
Concerning DSS, death related to the primary tumor was exclu-
sively considered as an event, and all other causes of death were
counted as censored. With regard to RFS, events were defined as
local and/or regional recurrences, occurrence of distant metasta-
sis, or death related to primary diagnosis, whereas death from
any other cause and patients alive without any disease manifes-
tation were included as censored observations. Calculating LCR,
local recurrences were considered as events. In the present
study, 5-year estimates are stated. Statistical differences
between groups were calculated by the log-rank test. The level of
significance was determined at 5%. Regarding statistical analysis
and to create graphics, the software Dell Statistica version 13.3
(Dell, Round Rock, TX; RRID:SCR_014213) was used. Final
editing was performed with the software Adobe Illustrator CC
version 18.1 (Adobe Systems, San José, CA; RRID:SCR_010279).
RESULTS
Patients
Sixty-five patients diagnosed with pT1–pT2 pN1 M0
malignancies were included in the study. Reagrding
tumor location, 27.7% (n = 18) were located in the oral
cavity, 46.2% (n = 30) in the oropharynx, and 26.2%
(n = 17) in the hypopharynx.
Therapy
All patients received resection of the local primary
tumor by TLM and selective ND. ND was performed uni-
laterally in 70.8% (n = 46) and bilaterally in 29.2%
(n = 19) of all patients. Level II and III were completed in
all patients, except for one (98.5%, n = 64). Additionally,
TABLE II.




PORT, n = 44
Total,
N = 65
Status at Last Follow-up
Alive without index cancer 8 (38.1%) 18 (40.9%) 26 (40.0%)
Cancer-related death 1 (4.8%) 12 (27.3%) 13 (20.0%)
Death related to secondary
primary
2 (9.5%) 3 (6.8%) 5 (7.7%)
Intercurrent death 10 (47.6%) 11 (25.0%) 21 (32.3%)
Local, locoregional, or regional
recurrences
No 19 (90.5%) 20 (45.5%) 39 (60.0%)
Yes 2 (9.5%) 24 (54.5%) 26 (40.0%)
Time initial surgery until
recurrence, mo, mean  SD
17.7  13.3 16.7  13.9 17.5  13.3
Distant metastasis
No 20 (95.2%) 37 (84.1%) 57 (87.7%)
Yes 1 (4.8%) 7 (15.9%) 8 (12.3%)
Time initial surgery until distant
disease, mo, mean  SD
27.2  0.0 36.7  33.7 35.5  31.4
PORT = postoperative (chemo)radiotherapy; SD = standard deviation.
Laryngoscope 130: October 2020 Weiss et al.: Postoperative Therapy for pT1–pT2 pN1 HNSCC
E532
considering the total amount of 84 treated neck sides,
level I was included in 32.1% (n = 27), level IV in 27.4%
(n = 23), and level V in 11.9% (n = 10). In all cases, histo-
pathological assessment revealed malignant cells in a
single ipsilateral lymph node without ECS. The location
of the lymph node metastasis for oral cavity tumors was
27.8% (n = 5) in level I, 27.8% (n = 5) in level II, 33.3%
(n = 6) in level II–III, and 5.6% (n = 1) in level III. It
could not be specified in one case (5.6%, level I–IV en
block ND specimen). The lymph node metastasis of oro-
pharyngeal tumors was located in 26.7% (n = 8) in level
II and in 50.0% (n = 15) level II–III. It was not further
specified in seven cases (23.3%), in which en bloc ND
specimens comprise three to five levels. For hypo-
pharyngeal tumors it was 35.3% (n = 6) level II, 11.8%
(n = 2) level III, and 41.2% (n = 7) level II–III. It was not
specified for two cases (11.8%) that received a level II–IV
neck dissection.
Postoperative radiotherapy was implemented in the
treatment of 32.3% (n = 21 of 65) patients. By main locali-
zations, 22.2% (n = 4) of 18 patients with OSCC, 46.7%
(n = 14) of 30 patients with OPSCC, and 17.6% (n = 3) of
17 patients with HPSCC received this postoperative
treatment. It was combined with concomitant chemother-
apy in 57.1% of the cases (n = 12). No patient received
chemotherapy without radiotherapy.
The mean follow-up time until death (or lost to follow-
up) was 80.7  50.7monthswith amaximumof 208months.
Stratified by treatment group (PORT, no PORT, and com-
plete cohort), patients and disease characteristics, as well as
follow-up data are presented in Table I. The analyzed char-
acteristics were not significantly different distributed
Fig. 1. Five-year Kaplan-Meier estimates of overall survival (A), disease-specific survival (B), recurrence-free survival (C), and local control rate
(D) stratified by treatment group. P values calculated by log-rank test. PORT = postoperative (chemo)radiotherapy.
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between both treatment groups (for P values of the Pearson
χ2 test see Table I).
Oncological Results
Treatment failures occurred in 9.5% (n = 2) of
patients with PORT, whereas 54.5% (n = 24) of the
unirradiated patients experienced recurrence. Of those
patients, 11.4% (n = 5) later developed a second recur-
rence, whereas no patient treated by PORT had a second
recurrence. Moreover, unirradiated patients were more
frequently diagnosed with distant metastases (15.9%
vs. 4.8%, Pearson χ2 test: P = .201). Out of eight cases in
total with distant metastases, one occurred in a postoper-
atively irradiated patient who developed neither local nor
regional recurrence, but was diagnosed with multiple dis-
tant metastasis after 27.2 months of initial surgical resec-
tion. The remaining seven cases occurred in unirradiated
patients after a mean time of 36.7  33.7 months follow-
ing initial surgical resection. Prior to the distant disease,
all of those unirradiated patients were diagnosed with a
local or a regional recurrence. The occurrence of second-
ary primary tumors in the head and neck was comparable
within both treatment groups (14.3% [n = 3] of the irradi-
ated vs. 13.6% [n = 6] of unirradiated patients, Pearson χ2
test: P = .943). Details of oncological outcomes stratified
by treatment group are depicted in Table II.
The complete study group’s 5-year OS, DSS, RFS, and
LCR was 65.5%, 80.0%, 56.9%, and 73.4%, respectively. In
an analysis of the oncological outcome estimates of patients
with or without PORT by log-rank test, no significant differ-
ence of OS was observed (71.4% vs. 62.6%, P = .533). With
regard to DSS as well as RFS, irradiated patients showed a
significant superiority over the unirradiated ones (DSS:
94.4% vs. 73.2%, P = .029; RFS: 85.2% vs. 43.2%, P = .002).
Moreover, the LCR was significantly higher in patients who
underwent PORT (90.2% vs. 64.9%, P = .04). Figure 1 illus-
trates the Kaplan-Meier curves for OS, DSS, RFS, and the
LCR stratified by treatment groups. When comparing the
survival rates of patients with chemotherapy-enhanced
PORT (n = 12) versus PORTalone (n = 9), no statistically sig-
nificant differenceswere observed (data not shown).
Subgroup Analyses
pT category. To analyze potential differences with
regard to local tumor extent, patients were stratified
according to the pT category. Within the subset of
28 patients with pT1 carcinomas, 28.6% (n = 8) under-
went PORT. Comparing the survival estimates of irradi-
ated patients to those who did not receive PORT (71.4%,
n = 20), there was no significant difference between the
OS and DSS, even though results were higher for the
PORT group. Regarding RFS, a significant superiority of
this subgroup’s irradiated patients was evident (100%
vs. 48.5%, P = .013). Additionally, a trend toward an
improved LCR was observed (100% vs. 65.9%, P = .06).
Among the 37 patients with pT2 carcinomas, 35.1%
(n = 13) underwent PORT. Regarding OS and LCR, there
was no significant difference between irradiated and
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the PORT group. Concerning DSS, the group with PORT
exhibited a trend toward an improved survival (90.0%
vs. 59.9%, P = .053). Furthermore, RFS was significantly
higher in patients with PORT (75.5% vs. 38.5%,P = .04).
Supporting Figure 1 illustrates the Kaplan-Meier
curves of OS, DSS, RFS, and LCR for the pT1 and pT2
cohort stratified by treatment groups. Oncological results
of the studies’ complete cohort as well as of subgroup
analysis are presented in Table III.
OPSCC subsite. Most of the included patients were
diagnosed with OPSCC (46.2%, n = 30). Demonstrating a
relatively equal distribution of 14 (46.7%) patients with
and 16 (53.3%) without PORT, a subset analysis of onco-
logical long-term outcomes was performed. Occurrence of
treatment failures and distant metastasis stratified by
treatment group are presented in Table IV with regard to
each of the three main localizations (oral cavity, orophar-
ynx, and hypopharynx).
Analyzing the differences of oncological results
between the two treatment groups with OPSCC, the
PORT group showed a significant superiority for RFS and
a statistical trend toward higher DSS (RFS: 77.4%
vs. 31.3%, P = .011; DSS: 91.7% vs. 62.5%, P = .06). No
statistically significant difference in OS and LCR was
observed, even though results were higher for the PORT
group. Supporting Figure 2 illustrates the Kaplan-Meier
curves, and Table III illustrates the 5-year estimates of
OS, DSS, RFS, and LCR for the subanalyses of OSCC,
OPSSC, and HPSCC patients stratified by treatment
groups.
In 43.3% (n = 13) of OPSCC cases, the p16 status
could be determined. It was relatively equally distributed
between both treatment groups (Pearson χ2 test: P = .569;
Table I). The 5-year estimates of p16-positive (n = 9) ver-
sus p16-negative (n = 4) cases were as follows: OS: 88.9%
vs. 50.0%, DSS: 88.9% vs. 66.7%, RFS: 55.6% vs. 33.3%,
and LCR: 76.2% vs. 100%. Estimates stratified by treat-
ment group were not calculated due to the small sample
sizes.
DISCUSSION
This study presents a retrospective analysis of
patients with locally circumscribed head and neck SCC
(pT1–pT2) and a single ipsilateral lymph node metastasis
(pN1) without ECS. The benefit of postoperative radio-
therapy in these patients has been controversially dis-
cussed to this day.6 Studies addressing this topic are
scarce and exclusively of retrospective nature.9–14 Addi-
tionally, the described disease constellation is relatively
rare. Out of 807 patients who received primary TLM for
OSCC, OPSCC, or HPSCC, and whose outcome was
reviewed previously,1,2,15 only 65 (8.1%) met these
criteria. Patients treated between 1986 and 2015 were
included in this study. Throughout this time period,
knowledge leading to more standardized recommenda-
tions for PORT was still evolving. Therefore, patients
exist who received or did not receive this additional treat-
ment. Their data provide the opportunity to evaluate the
differences of long-term oncological outcome between, in
particular, those two treatment groups retrospectively.
In the present study, PORT was associated with a
significant superior DSS, RFS, and LCR. Regarding OS,
it was 71.4% for patients receiving PORT and 62.6% for
those treated by surgery alone. Nevertheless, albeit close,
the difference was not statistically significant. On the one
hand, 40% of the patients died by other causes not related
to the primary disease or in association with a second
malignancy, whereas on the other hand, the limited sta-
tistical power to reach significance was most probably
owed due to the disease’s rareness in a single center, thus
resulting in a smaller cohort. Based on larger study
populations derived from the Surveillance, Epidemiology,
and End Results Database11 or the National Cancer
Database,12 two studies reported a significant improve-
ment of OS for patients who underwent PORT. However,
in an approach more comparable to the present study of a
single-center retrospective study, Chen et al. reported sig-
nificantly superior OS estimates of 20 irradiated patients
over those of 19 unirradiated patients with pT1–pT2 pN1
ECS-negative tongue SCC as well.10 Concerning DSS, the
present results are in accordance with the studies men-
tioned above,10,11 where it was found to be significantly
higher for patients with PORT. Unfortunately, the study
investigating the results of the National Cancer Database
does not provide DSS at all.12 Moreover, the present anal-
ysis exhibited significant higher RFS for patients with
PORT. Only one other study investigated RFS in this con-
text. Even though it was limited to pT1 carcinomas, it
also reported a significant difference.14 Furthermore,
TABLE IV.
Distribution of Treatment Failures Stratified by Main Localization and Treatment Group.
OSCC OPSCC HPSCC All Localizations
PORT, n = 4 No PORT, n = 14 PORT, n = 14 No PORT, n = 16 PORT, n = 3 No PORT, n = 14 PORT, n = 21 No PORT, n = 44
Recurrence
Local 0 4 1 3 0 5 1 12
Locoregional 0 0 1 2 0 0 1 2
Regional 0 2 0 6 0 2 0 10
Total 0 (0%) 6 (42.9%) 2 (14.3%) 11 (68.8%) 0 (0%) 7 (50.0%) 2 (9.5%) 24 (54.5%)
Distant metastasis 0 (0%) 1 (7.1%) 1 (7.1%) 3 (18.8%) 0 (0%) 3 (21.4%) 1 (4.8%) 7 (15.9%)
HPSCC = hypopharyngeal squamous cell carcinoma; OPSCC = oropharyngeal squamous cell carcinoma; OSCC = oral squamous cell carcinoma;
PORT = postoperative (chemo)radiotherapy.
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according to our knowledge, the present study is cur-
rently the only one considering 5-year LCR as an end-
point. It was significantly higher in the subgroup of
PORT-treated patients. Taken together, the current study
as well as previous studies in the literature suggest bet-
ter oncological outcome for patients with pT1–pT2 pN1
carcinomas treated additionally with PORT. Overall, the
present study evaluated ECS-negative patients alone in
contrast to the heterogenic cohort of Shrime et al., who
was unable to exclude patients with ECS because the
reviewed database did not provide this information.11
Benefit of adding platinum-based chemotherapy to
postoperative radiotherapy was demonstrated with level
1 evidence for cases with extracapsular tumor spread
and/or microscopically involved surgical margins.5,27,28 In
our center for the effect of radiosensitization provided by
additional chemotherapy, this concomitant treatment was
applied generously, even in cases without the major risk
factors mentioned above. In due consideration of the small
number of cases and therefore limited statistical conclu-
sions, survival of patients treated with chemotherapy-
enhanced PORT versus PORT alone did not differ in the
current study.
To investigate the influence of local tumor extent,
subgroups with either pT1 or pT2 carcinomas were ana-
lyzed separately. Superior 5-year estimates were calcu-
lated for the group of irradiated patients compared to
those of the unirradiated ones. For RFS, this difference
was statistically significant in the pT1 and pT2 subgroups,
respectively. Consequently, PORT appeared beneficial in
cases of a single ipsilateral lymph node metastasis inde-
pendently of local tumor extent. Whereas for a pT2 sub-
group, significantly improved OS and DSS were reported
in other studies, this was not significant within their pT1
subgroup.11,12 In line with the present study, for pT1 carci-
nomas, Kadletz et al. described significantly higher RFS
estimates for patients who received PORT as well.14
Most of the previous studies focused on patients with
OSCC10–13 and/or OPSCC.12,14 In the present study, carci-
nomas localized in the oral cavity, oropharynx, and hypo-
pharynx were included and analyzed together as well as
separately. These subset analyses exhibited comparable
results. An overview about studies evaluating long-term
oncological results is given in Table III.
HPV-associated (p16 positive) OPSCC are often
related to a more favorable prognosis.29 Due to the long
timespan of inclusion, neither HPV nor p16 diagnostics
were included to the routine pathological assessment for
the whole cohort. Therefore, we performed p16 immuno-
histochemistry for those cases in which tissue was still
available. Among both treatment groups, the p16 status
was relatively equally distributed. Due to the small sample
size with a known p16 status, statistical analysis stratified
by treatment group (with or without PORT) was not per-
formed. According to our knowledge, there is currently no
study available assessing the association between PORT
and the long-term oncological outcome for a homogenous
cohort of patients with pT1–T2 pN1 OPSCC that takes
into account the carcinoma’s p16 status. Only Kadletz
et al. addressed this topic without providing data for the
pT1 pN1 subgroup. Moreover, this study did not include
pT2 pN1 carcinomas.14 Thus, a potential prognostic impact
of p16/HPV needs to be addressed in future studies.
The relevance of the present study is emphasized by
the lack of detailed high-evidence data for postoperative
radiotherapy in patients with the rare disease constella-
tion of pT1–pT2 pN1 ECS negative R0-resected head and
neck SCC. This is reflected by a paucity of published
data, with only five retrospective studies addressing this
topic at all.9–12,14 A considerable limit in data quality and
a high risk of bias inherent to retrospective studies need
to be considered in the present study. However, we faced
this limitation by strict inclusion criteria and detailed
data deriving from the original patients’ charts as well as
surgical and pathological reports. This enabled us to pre-
sent detailed long-term oncological outcome information
for patients with and without PORT, and therefore pro-
vide data that will potentially aid clinical decision mak-
ing as well as generate hypotheses for future prospective
research. Because no information with regard to side
effects and health-related quality of life was available for
the current analysis, this needs to be addressed in future
investigations.
CONCLUSION
Our results support the potential benefit of PORT
for patients after a margin-negative surgical resection of
locally circumscribed carcinomas with a single, ipsilat-
eral, ECS negative lymph node metastasis.
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